# Sacubitril/Allisartan for Hypertensive Patients With Overweight or Obesity

Study · id `cardio:ct-nct07241338` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07241338](<https://clinicaltrials.gov/study/NCT07241338>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07241338

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 104 participants.

## Technical summary

Registry record NCT07241338. Randomized; no masking; primary purpose treatment. Start 2025-11 (anticipated); primary completion 2026-11 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 104 participants (planned count; ClinicalTrials.gov record NCT07241338, source copy `cardio:ctgov-nct07241338-2025-11-21`, retrieved 2026-10-26)
- Planned start: 2025-11 (anticipated) (ClinicalTrials.gov record NCT07241338, source copy `cardio:ctgov-nct07241338-2025-11-21`, retrieved 2026-10-26)
- Primary completion: 2026-11 (anticipated) (ClinicalTrials.gov record NCT07241338, source copy `cardio:ctgov-nct07241338-2025-11-21`, retrieved 2026-10-26)
- Completion: 2027-06 (anticipated) (ClinicalTrials.gov record NCT07241338, source copy `cardio:ctgov-nct07241338-2025-11-21`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07241338, source copy `cardio:ctgov-nct07241338-2025-11-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07241338-2025-11-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Sacubitril/Allisartan for Hypertensive Patients With Overweight or Obesity
- Acronym: SHOT
- Condition: Hypertension
- Intervention (Drug): sacubitril/allisartan
- Intervention (Drug): Amlodipine
- Lead sponsor: Jing Liu
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Amlodipine (`cardio:amlodipine`)

## Provenance

Content hash: d05bc4281eaa0f8a3bc22a7cc72659fea31341d0228249c41927c8ade9fef678
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
